<DOC>
	<DOC>NCT02028884</DOC>
	<brief_summary>The objective of this study is to evaluate the efficacy, safety, pharmacodynamic, pharmacokinetic and immunogenic profiles of SA237 in patients with NMO and NMOSD</brief_summary>
	<brief_title>Efficacy and Safety Study as Add-on Therapy of SA237 to Treat NMO and NMOSD</brief_title>
	<detailed_description>Recruitment is closed to adults. Recruitment is open to adolescents 12-17 years old.</detailed_description>
	<mesh_term>Neuromyelitis Optica</mesh_term>
	<criteria>1. NMO or NMOSD 2. Age 12 to 74 years, inclusive at the time of informed consent. Exclusion Criteria 1. Pregnancy or lactation. 2. Evidence of other demyelinating disease or progressive multifocal leukoencephalopathy (PML). 3. Known active infection (excluding fungal infections of nail beds or caries dentium) within 4 weeks prior to baseline.</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>